Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2015 (2015), Article ID 348124, 8 pages
http://dx.doi.org/10.1155/2015/348124
Clinical Study

Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial

1Department of Medical Oncology, Leiden University Medical Center, 2333 ZA Leiden, Netherlands
2Department of Pathology, Leiden University Medical Center, 2333 ZA Leiden, Netherlands
3Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, 2333 ZA Leiden, Netherlands
4Department of Endocrinology, University Medical Center Groningen, 9700 RB Groningen, Netherlands
5Department of Clinical Pharmacy, Radboud University Nijmegen Medical Center, 6525 GA Nijmegen, Netherlands

Received 5 November 2014; Accepted 17 June 2015

Academic Editor: Constantinos Pantos

Copyright © 2015 T. C. Schneider et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Schlumberger, F. Carlomagno, E. Baudin, J. M. Bidart, and M. Santoro, “New therapeutic approaches to treat medullary thyroid carcinoma,” Nature Clinical Practice Endocrinology & Metabolism, vol. 4, no. 1, pp. 22–32, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. D. L. Segev, C. Umbricht, and M. A. Zeiger, “Molecular pathogenesis of thyroid cancer,” Surgical Oncology, vol. 12, no. 2, pp. 69–90, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. D. J. Marsh, L. M. Mulligan, and C. Eng, “RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma,” Hormone Research, vol. 47, no. 4–6, pp. 168–178, 1997. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Xing, “Recent advances in molecular biology of thyroid cancer and their clinical implications,” Otolaryngologic Clinics of North America, vol. 41, no. 6, pp. 1135–1146, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. M. N. Hall, “mTOR—what does it do?” Transplantation Proceedings, vol. 40, no. 10, supplement, pp. S5–S8, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Grozinsky-Glasberg, G. Franchi, M. Teng et al., “Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell line,” Neuroendocrinology, vol. 87, no. 3, pp. 168–181, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. J. C. Yao, A. T. Phan, D. Z. Chang et al., “Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low-to intermediate-grade neuroendocrine tumors: results of a phase II study,” Journal of Clinical Oncology, vol. 26, no. 26, pp. 4311–4318, 2008. View at Publisher · View at Google Scholar
  8. J. C. Yao, C. Lombard-Bohas, E. Baudin et al., “Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial,” Journal of Clinical Oncology, vol. 28, no. 1, pp. 69–76, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Zitzmann, E. N. De Toni, S. Brand et al., “The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells,” Neuroendocrinology, vol. 85, no. 1, pp. 54–60, 2007. View at Publisher · View at Google Scholar
  10. E. A. Eisenhauer, P. Therasse, J. Bogaerts et al., “New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1),” European Journal of Cancer, vol. 45, no. 2, pp. 228–247, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Faggiano, V. Ramundo, A. Dicitore et al., “Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study,” Journal of Cellular and Molecular Medicine, vol. 16, no. 7, pp. 1563–1572, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Grozinsky-Glasberg, H. Rubinfeld, Y. Nordenberg et al., “The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells,” Molecular and Cellular Endocrinology, vol. 315, no. 1-2, pp. 87–94, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Druce, T.-T. Chung, S. Grozinsky-Glasberg, D. J. Gross, and A. B. Grossman, “Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma,” Clinical Endocrinology, vol. 77, no. 1, pp. 154–155, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. S. M. Lim, H. Chang, M. J. Yoon et al., “A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes,” Annals of Oncology, vol. 24, no. 12, Article ID mdt379, pp. 3089–3093, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Elisei, M. J. Schlumberger, S. P. Müller et al., “Cabozantinib in progressive medullary thyroid cancer,” Journal of Clinical Oncology, vol. 31, no. 29, pp. 3639–3646, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Kurzrock, S. I. Sherman, D. W. Ball et al., “Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer,” Journal of Clinical Oncology, vol. 29, no. 19, pp. 2660–2666, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Rodríguez-Antona, J. Pallares, C. Montero-Conde et al., “Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis,” Endocrine-Related Cancer, vol. 17, no. 1, pp. 7–16, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. M. M. de Gunst, M. I. Gallegos-Ruiz, G. Giaccone, and J. A. Rodriguez, “Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain,” Molecular Cancer, vol. 6, article 56, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Han, X. Zhou, R.-X. Zhang et al., “Mutations of the epidermal growth factor receptor gene in NSCLC patients,” Oncology Letters, vol. 2, no. 6, pp. 1233–1237, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. F. Raue and K. Frank-Raue, “Genotype-phenotype correlation in multiple endocrine neoplasia type 2,” Clinics, vol. 67, pp. 69–75, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. V. Grünwald, S. Weikert, M. E. Pavel et al., “Practical management of everolimus-related toxicities in patients with advanced solid tumors,” Onkologie, vol. 36, no. 5, pp. 295–302, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. A. O'Donnell, S. Faivre, H. A. Burris III et al., “Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors,” Journal of Clinical Oncology, vol. 26, no. 10, pp. 1588–1595, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. I. Okamoto, T. Doi, A. Ohtsu et al., “Phase I clinical and pharmacokinetic study of Rad001 (everolimus) administered daily to Japanese patients with advanced solid tumors,” Japanese Journal of Clinical Oncology, vol. 40, no. 1, Article ID hyp120, pp. 17–23, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Tobinai, M. Ogura, D. Maruyama et al., “Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma,” International Journal of Hematology, vol. 92, no. 4, pp. 563–570, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Hisamatsu, S. Mabuchi, Y. Matsumoto et al., “Potential role of mTORC2 as a therapeutic target in clear cell carcinoma of the ovary,” Molecular Cancer Therapeutics, vol. 12, no. 7, pp. 1367–1377, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Carracedo, L. Ma, J. Teruya-Feldstein et al., “Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer,” The Journal of Clinical Investigation, vol. 118, no. 9, pp. 3065–3074, 2008. View at Publisher · View at Google Scholar · View at Scopus